Th1 not Th17 cells drive spontaneous MS-like disease despite a functional regulatory T cell response.
Multiple sclerosis is considered a disease of complex autoimmune etiology, yet there remains a lack of consensus as to specific immune effector mechanisms. Recent analyses of experimental autoimmune encephalomyelitis, the common mouse model of multiple sclerosis, have investigated the relative contribution of Th1 and Th17 CD4 T cell subsets to initial autoimmune central nervous system (CNS) damage. However, inherent in these studies are biases influenced by the adjuvant and toxin needed to break self-tolerance. We investigated spontaneous CNS disease in a clinically relevant, humanized, T cell receptor transgenic mouse model. Mice develop spontaneous, ascending paralysis, allowing unbiased characterization of T cell immunity in an HLA-DR15-restricted T cell repertoire. Analysis of naturally progressing disease shows that IFNγ(+) cells dominate disease initiation with IL-17(+) cells apparent in affected tissue only once disease is established. Tregs accumulate in the CNS but are ultimately ineffective at halting disease progression. However, ablation of Tregs causes profound acceleration of disease, with uncontrolled infiltration of lymphocytes into the CNS. This synchronous, severe disease allows characterization of the responses that are deregulated in exacerbated disease: the correlation is with increased CNS CD4 and CD8 IFNγ responses. Recovery of the ablated Treg population halts ongoing disease progression and Tregs extracted from the central nervous system at peak disease are functionally competent to regulate myelin specific T cell responses. Thus, in a clinically relevant mouse model of MS, initial disease is IFNγ driven and the enhanced central nervous system responses unleashed through Treg ablation comprise IFNγ cytokine production by CD4 and CD8 cells, but not IL-17 responses.
Human Disease Immunogenetics Group, Section of Infectious Diseases and Immunity, Department of Medicine, Imperial College, Hammersmith Hospital, London, W12 0NN, UK.
Daniel E
DE
Lowther
Deborah L
DL
Chong
Stephanie
S
Ascough
Anna
A
Ettorre
Rebecca J
RJ
Ingram
Rosemary J
RJ
Boyton
Daniel M
DM
Altmann
D000818:Animals; D001921:Brain / Q000473:pathology; D015496:CD4-Positive T-Lymphocytes / Q000502:physiology; D018414:CD8-Positive T-Lymphocytes / Q000502:physiology; D049109:Cell Proliferation; D002490:Central Nervous System / Q000473:pathology; D018450:Disease Progression; D005455:Fluorescent Antibody Technique; D059810:HLA-DR Serological Subtypes / Q000378:metabolism; D006801:Humans; D007371:Interferon-gamma / Q000502:physiology; D020381:Interleukin-17 / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D009103:Multiple Sclerosis / Q000134:cerebrospinal fluid / Q000276:immunology / Q000473:pathology*; D060888:Real-Time Polymerase Chain Reaction; D011948:Receptors, Antigen, T-Cell / Q000235:genetics; D050378:T-Lymphocytes, Regulatory / Q000502:physiology*; D018417:Th1 Cells / Q000502:physiology*; D058504:Th17 Cells / Q000502:physiology*
D059810:HLA-DR Serological Subtypes; C106559:HLA-DR15 antigen; D020381:Interleukin-17; D011948:Receptors, Antigen, T-Cell; D007371:Interferon-gamma